Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

iTeos Therapeutics Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

iTeos Therapeutics hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	2.9%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$3.63
Erwartete Dividendenrendite in 3 Jahren	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough

Jan 25

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

Jan 10

Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%

May 13

Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding

Mar 21

The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically

Aug 12

iTeos Therapeutics GAAP EPS of $0.16 misses by $1.04

Aug 10

iTeos Therapeutics: Too Many Unknowns

Jul 27

News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts

May 11

Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic

Nov 25

We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth

Aug 24

iTeos Therapeutics: My Calculations Suggest Q3 Earnings Will Exceed $10 Per Share

Aug 15

GlaxoSmithKline - iTeos deal intensifies competition in anti-TIGIT space: Piper Sandler

Jun 15

We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth

Feb 07

Is iTeos Therapeutics, Inc. (NASDAQ:ITOS) Popular Amongst Institutions?

Dec 16

iTeos Therapeutics EPS misses by $0.11

Nov 12

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von ITOS in der Vergangenheit stabil geblieben ist.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von ITOS gestiegen sind.

Dividendenrendite im Vergleich zum Markt

iTeos Therapeutics Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von ITOS im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (ITOS)	n/a
Untere 25 % des Marktes (US)	1.5%
Markt Top 25 % (US)	4.7%
Branchendurchschnitt (Biotechs)	2.9%
Analystenprognose in 3 Jahren (ITOS)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von ITOS im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von ITOS im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von ITOS, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da ITOS keine Ausschüttungen gemeldet hat.

iTeos Therapeutics Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

New minor risk - Shareholder dilution

iTeos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $119.994271 million.

iTeos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $119.994271 million.

New major risk - Revenue size

Insufficient new directors

iTeos Therapeutics, Inc., Annual General Meeting, Jun 11, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

iTeos Therapeutics, Inc. Appoints Jill DeSimone to its Board of Directors, Effective March 7, 2024

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

Iteos Therapeutics, Inc. Announces Business Updates and Strategic Priorities for 2024

Iteos Therapeutics, Inc. Announces Board Changes

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.90 loss per share (vs US$0.028 profit in 3Q 2022)

New minor risk - Share price stability

Price target decreased by 11% to US$35.75

Second quarter 2023 earnings released: US$0.96 loss per share (vs US$0.16 profit in 2Q 2022)

Investor sentiment improves as stock rises 18%

Consensus revenue estimates increase by 46%

Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%

Price target decreased by 8.9% to US$40.27

Chief Operating Officer exercised options to buy US$531k worth of stock.

Investor sentiment deteriorates as stock falls 17%

Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding

High number of new directors

iTeos Therapeutics, Inc. Announces Resignation of Matthew Roden from the Board

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorated over the past week

High number of new directors

Consensus revenue estimates fall by 23%

The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically

iTeos Therapeutics GAAP EPS of $0.16 misses by $1.04

iTeos Therapeutics: Too Many Unknowns

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Independent Chairman of the Board notifies of intention to sell stock

Investor sentiment improved over the past week

High number of new directors

Price target decreased to US$46.20

Investor sentiment deteriorated over the past week

News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts

Consensus revenue estimates increase by 30%

Price target increased to US$50.20

President notifies of intention to sell stock

iTeos Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

President exercised options and sold US$318k worth of stock

Price target increased to US$50.20

Consensus revenue estimates fall by 29%

Chief Medical Officer exercised options and sold US$111k worth of stock

Chief Scientific Officer exercised options and sold US$325k worth of stock

Chief Medical Officer exercised options and sold US$110k worth of stock

President notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$123k worth of stock

Chief Medical Officer exercised options and sold US$333k worth of stock

Chief Financial Officer recently sold US$232k worth of stock

Price target increased to US$50.00

Chief Medical Officer exercised options and sold US$106k worth of stock

Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic

Chief Medical Officer exercised options and sold US$846k worth of stock

President notifies of intention to sell stock

Chief Financial Officer exercised options to buy US$381k worth of stock.

President notifies of intention to sell stock

President notifies of intention to sell stock

We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth

Consensus EPS estimates fall to -US$2.27

iTeos Therapeutics: My Calculations Suggest Q3 Earnings Will Exceed $10 Per Share

Forecast to breakeven in 2021

Chief Operating Officer exercised options to buy US$1.3m worth of stock.

High number of new directors

iTeos Therapeutics, Inc.(NasdaqGM:ITOS) dropped from Russell 2500 Growth Index

Chief Financial Officer recently bought US$130k worth of stock

Forecast to breakeven in 2021

iTeos Therapeutics and GSK Announce Development and Commercialization Collaboration for Eos-448, an Anti-Tigit Monoclonal Antibody, Enabling Novel Next-Generation Immuno-Oncology Combinations

GlaxoSmithKline - iTeos deal intensifies competition in anti-TIGIT space: Piper Sandler